Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA

Near- and mid term expected milestones
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, Nasdaq Copenhagen:
ONXEO, “Onxeo” or ”the Company”), an innovative company specializing in the
development of orphan oncology therapeutics, today announced its plan for
further development of AsiDNA, its first-in-class signal interfering DNA
molecule which breaks the cycle of tumor DNA repair to induce cancer cell death.

In March 2016, Onxeo successfully completed the acquisition of DNA Therapeutics
for its key innovative DNA repair inhibitor technology platform and lead
compound AsiDNA. Following the acquisition, Onxeo has strategically assessed
development options and is now accelerating a deep and comprehensive advancement
plan for its newest compound both as monotherapy and in combination with anti
-cancer agents.

AsiDNA: first-in-class signal interfering DNA repair compound with blockbuster
potential

Onxeo’s signal-interfering DNA (siDNA) product candidate, AsiDNA, is a short
double-stranded DNA molecule which breaks the cycle of tumor DNA repair by
interfering at the core of DNA damages, blocking multiple repair pathways, while
sparing healthy cells. AsiDNA and its signal-interfering technology offer
potential new treatment options for patients suffering from various types of
cancer.

This technology has already demonstrated an increase in the efficacy of
radiotherapy1, radiofrequency ablation2, and chemotherapy3 in a variety of
preclinical animal models, making it a promising candidate for both mono and
combination therapy. A first-in-human Phase I/IIa trial4 (DRIIM) performed in
metastatic melanoma further demonstrated that AsiDNA molecules showed good
tolerance and safety when administered intra-tumorally and subcutaneously around
the tumors, with no evidence of inflammatory phenomena. Results presented at
ASCO 20155 showed, based on 23 patients, an objective response rate (ORR) of 59%
and a complete response (CR) rate of 30% compared to 10% CR with radiotherapy
alone6.

Development plan focused on systemic route administration

Preclinical: Based on these first local positive results as well as promising
preclinical experiment outcomes, Onxeo is initating the development of AsiDNA
through a systemic administration, enabling its potential as a therapy across a
broad range of oncology indications. Preclinical programs have been initiated to
further define the pharmacokinetic/pharmacodynamic profile following an
intravenous administration. Results are expected in Q3/Q4 2016.

Manufacturing: In parallel, the Company is collaborating with one of the top
U.S. manufacturing expert facilities for complex life science products, in order
to optimize the manufacturing process of AsiDNA. Overall, the goal is to improve
costs and production duration for future large-scale clinical development and
industrialization. First results for this process development are expected in Q4
2016.

Clinical: Based on the already deep knowledge generated and the study outcomes
set forth above, Onxeo is exploring opportunities to accelerate the clinical
development of AsiDNA and is planning to launch the Company’s first clinical
trial of AsiDNA as soon as 2017 to assess safety and first indication of anti
-cancer activity of AsiDNA as monotherapy via systemic administration.

Judith Greciet, CEO of Onxeo, commented, “We have built an ambitious plan for
AsiDNA to demonstrate its value in several types of cancer through a systemic
administration. This plan aims at accelerating development with presentation of
preclinical data within the next 6 months and a view to entering the clinic
shortly therafter. First clinical data of AsiDNA in systemic use represent a
major step in our development strategy as these results have the ability to
confirm the tremendous potential of the product. Signal interfering DNA repair
technology is increasingly becoming one of the most innovative research fields
and such data, as soon as 2017, could support sound value creation for AsiDNA,
for patients and for Onxeo as a company.”

Expected AsiDNA newsflow

Q3/Q4 2016: Results of preclinical trial of AsiDNA
Q4 2016: Optimization of manufacturing process
2017: Launch of AsiDNA clinical trial in monotherapy

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
vision is to become a global leader and pioneer in oncology, with a focus on
orphan or rare cancers, by developing advanced, effective, and safe therapeutics
designed to improve the lives of patients. Onxeo’s comprehensive portfolio
features a broad orphan oncology pipeline, with four independent programs in
various stages of clinical development, including Onxeo’s first approved orphan
oncology drug, Beleodaq®. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker:
ONXEO).

Onxeo’s orphan oncology products are:

  · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
and in combination with other cancer agents in first-line HCC
  · Beleodaq® (belinostat): FDA-approved in the US in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer
agents is currently in development in first-line treatment for patients with
PTCL (BelCHOP) and in other solid tumors
  · AsiDNA: The first-in-class siDNA (signal-interfering DNA) which has
successfully undergone a proof-of-concept Phase I/IIa trial in metastatic
melanoma
  · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis
 In addition, Onxeo has successfully developed and registered two non-cancer
products which are currently being commercialized in the U.S. and Europe.

Learn more by
visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%
3 
A%2F%2Fwww.onxeo.com&esheet=51370271&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=3e2a71242392d1c3572d4663a754af36).

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51370271&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=9c97537ce
c 
2c71faa9e52cf0c29546fb)

Follow us on Twitter: @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference
Document filed with the AMF on April 29, 2016, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51370271&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=59eba353fd748c9f736f5a58869a1a84)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51370271&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=b6c663503faccfa08745b07e6b7c7227)).

1 Quanz et al., 2009, Berthault et al., 2011, Coquery et al., 2012, Biau et al.,
2014
2 Devun et al., 2014
3 Devun et al. 2011, Herath et al., 2016

4 DRIIM Phase 1/2a trial, “DNA Repair Inhibitor & Irradiation on Melanoma”
NCT01469455)
5 Abstract available at http://meetinglibrary.asco.org/content/143029
-156 (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmeetinglib
r 
ary.asco.org%2Fcontent%2F143029-156&esheet=51370271&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fmeetinglibrary.asco.org%2Fcontent%2F143029
-156&index=5&md5=cec2c55aa0ae1e009b6bd1a7691d5be7)
6 Based on literature data.
Contacts

Onxeo
Judith Greciet, CEO
Nicolas Fellmann, CFO
contact@onxeo.com
+33 1 45 58 76 00
or
Alize RP (France)
Caroline Carmagnol /Florence Portejoie
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 47 38 90 04
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth
kthomas@theruthgroup.com / lroth@theruthgroup.com
+1 508 280 6592 / +1 646 536 7012